Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared ECOG-ACRIN Cancer Research Group’s post on X, adding:
“Huge opportunity to join this phase 3 trial to answer the question of ICI rechallenge in advanced urothelial Ca building on a +ve phase 2 trial. Patients randomized to SG/pembrolizumab vs salvage chemotherapy.”
ECOG-ACRIN Cancer Research Group shared a post on X:
“Monika Joshimd and Petros Grivas are leading Clinical Trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced urothelial cancer.”
More posts featuring Urothelial Cancer.